"Designing Growth Strategies is in our DNA"

Immunoglobulins Market Size, Share and Global Trend By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form(Liqui, Lyophilized), By End User(Hospitals, Clinics, Homecare) and Geography Forecast till 2026

Region : Global | Latest Update: Jul, 2019 | Published Date: Jun, 2019 | Report ID: FBI100571| Status : Published

 

KEY INDUSTRY INSIGHTS

The Global Immunoglobulins Market was valued at US$ 10,750.0 Mn in 2017 and is projected to reach US$ 18,378.0 Mn by the end of 2025, exhibiting a CAGR of 7.0%Immunoglobulins are the glycoprotein molecules manufactured by the plasma or the white blood cells. Immunoglobulins form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction.

In many of the individuals, the immunoglobulins have to be specially administered through a variety of route of administration for the body to be able to fight a number of immune diseases. Due to increasing awareness and an increasing number of diagnoses due to greater efficiency in diagnostic methods, there has been a greater demand for immunoglobulins as a treatment option.

Get comprehensive study about this report by, request a sample copy

This, coupled with the proven efficiency of the immunoglobulins as an effective treatment option for a number of diseases such as primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy (CIDP) is also positively driving the market growth. Some of the other factors which are also contributing to the growth of the immunoglobulins market is its immunomodulation and anti-inflammatory properties. The introduction of new and advanced immunoglobulins such as CUVITRU and BIVIGAM by Shire (Takeda Pharmaceutical Company Limited) and ADMA Biologics Inc., respectively is expected to drive the growth of the immunoglobulins market in developed as well as emerging countries, during the forecast period 2018-2025.  

Intravenous (IV) to Account for The Highest Market Share by 2025 

The adoption of immunoglobulin therapy as the first line of treatment for the primary immunodeficiency and other rare immunological and neurological diseases. This is one of the most prominent factors that are responsible for the growth of the global immunoglobulins market in 2017. Intravenous (IV) segment is estimated to have the largest market share among the route of administration segment. The intravenous (IV) segment accounted for the largest market share in 2017 and is expected to decline during the forecast period. Increasing focus towards the diagnosis of immune disorders and the subsequent treatment based on the individual case and training of the patient, in most cases the patient is not adept in self-administration, is also driving the intravenous segment. The subcutaneous (SC) segment is estimated to grow at a faster CAGR during the forecast period. This is attributed to the increasing number of product launches, especially in the subcutaneous (SC) segment. Currently, there is increasing adoption of the subcutaneous in the markets in the developing nations due to improved patient advantages such as no need of venous access, and this is expected to contribute to the growth of the market at higher CAGR during the forecast period.

To get details on market share, speak to our analyst

Increasing Diagnosis Of Immunodeficiencies Due To Greater Awareness, along with Increasing Adoption of Immunoglobulins Expected to Result in The Highest CAGR in the Asia Pacific 

The Immunoglobulins market in North America was valued at US$ 6,291.5 Mn in 2017 and is anticipated to account for a dominant share in the global immunoglobulins market during the forecast period. The primary driving factor for the significant and strong growth of the Immunoglobulins market is the fact that the first line of treatment for a number of critical immune disorders. With the increase in contributing factors of such as the increasing number of patients and the efficiency of the immunoglobulins as a treatment option, is expected to give rise to significant demand for immunoglobulins. In developed countries, the adoption of advanced immunotherapies is growing alongside the greater adoption of subcutaneous immunoglobulins. India and China in the Asia Pacific region are experiencing growth in the immunoglobulins due to increased diagnosis of immunodeficiencies in the population. In terms of the dominance of route of administration, intravenous (IV) is the most dominating type in these developing regions. However, in countries like Japan, there is increased adoption and expenditure towards advanced immunoglobulins and Japan holds significant revenue shares in these advanced immunoglobulins.

North America Immunoglobulins Market, 2017

To get geographical overview of this market, request a sample copy

Grifols S.A. Is Anticipated to Be the Leading Player in Global Immunoglobulins Market 

Grifols, S.A., emerged as the leading player with the highest market share in 2017, as the company has a number of product offerings in the immunoglobulins market across a wide range of indications and in the commonly used route of administration, and these product offerings dominate a substantial portion of market share. The company accounts for the highest revenue shares in the immunoglobulins from regions such as North America and Europe. In addition, other market players are also getting product approvals such as Shire (Takeda Pharmaceutical Company Limited). The company received regulatory approvals for the immunoglobulin product offering of CUVITRU. Other players operating in the Immunoglobulins market are CSL Behring, Grifols, S.A., Kedrion S.p.A, Octapharma, Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB SA, and Shanghai RAAS Blood Products Co., Ltd. 

MARKET OVERVIEW

Immunoglobulins also referred to as antibodies, are the glycoprotein molecules manufactured by the plasma or the white blood cells. Immunoglobulins form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction. In certain individuals, immunoglobulins have to be administered for the treatment and management of diseases such as primary immunodeficiency (PI). The report on global immunoglobulins market focuses on market size in terms of revenue (US$ Mn), of Immunoglobulins, for the period 2014-2025. 

The report offers information pertaining to various dynamics of the market including drivers, restraints, opportunities for market players in the immunoglobulins market, and trends. The report analyzes and evaluates the current market size, growth rate, and forecast of the global immunoglobulins market, with regards to indication (primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN) and others). On the basis of the route of administration, the market is categorized into an intravenous (IV) and subcutaneous (SC). On the basis of form, the market can be segmented into liquid and lyophilized. On the basis of the end user, the market can be segmented into hospitals, clinics, and homecare. 

The report also offers key insights related to an overview of the Immunoglobulins Market (2017) - for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, pipeline analysis, overview of regulatory scenario by key regions, key industry developments, number of primary immunodeficiency (PI) patients by key countries and reimbursement scenario.

KEY SEGMENTS WITHIN THE MARKET

To get information on various segments, share your queries with us

SEGMENTATION 

 SEGMENTATION  

 DETAILS

By Route of Administration

·         Intravenous (IV)

·         Subcutaneous (SC)

By Indication

·         Primary Immunodeficiency

·         Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

·         Guillain-Barré Syndrome (GBS)

·         Immune Thrombocytopenic Purpura (ITP)

·         Multifocal Motor Neuropathy (MMN)

·         Others

By Form

·         Liquid

·         Lyophilized

By End User

·         Hospitals

·         Clinics

·         Homecare

By Geography

·         North America (the U.S., and Canada)

·         Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)

·         Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)

·         Latin America (Brazil, Mexico, and Rest of Latin America

·         Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)

KEY COMPANIES COVERED

  • Shire (Takeda Pharmaceutical Company Limited)
  • CSL Behring
  • Grifols, S.A.
  • Kedrion S.p.A
  • Octapharma
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • LFB SA
  • Shanghai RAAS Blood Products Co., Ltd.
  • Other players

Key Industry Developments

  • In May 2019, the FDA approved the prior approval supplement (PAS) for ADMA Biologics, Inc.’s product offering of BIVIGAM and subsequently ADMA announced that it will begin the commercial sales of the product
  • In April 2019, a novel intravenous immunoglobulin by ADMA Biologics, Inc. to be utilised for the treatment of primary immunodeficiency called Asceniv (Immune Globulin Intravenous, Human – slra 10%, Liquid), received the FDA approval
  • In May 2018, Kedrion S.p.A and Kamada announced that KEDRAB, an immunoglobulin aimed at the treatment of rabies, was ready for commercial distribution and shipping

Immunoglobulins Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2017
  • 2014-2016
  • 158

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X